biopharmaceuticals

In episode 1 of our yet-to-win award podcast, we talk to Dr. Sandeep Kumar, Distinguished Research Fellow in Biotherapeutics at Boehringer Ingelheim about how he uses computers to help develop and deliver biopharmaceuticals and his thoughts on the increasing importance of computational methods in drug discovery.  It gets controversial at times, so, you know, just a warning on that.

See more:

Computational Antibody Discovery: State of the Art: https://www.antibodysociety.org/computational-antibody-discovery-state-of-the-art/

In this episode, GOLD is joined by Isabel Afonso, General Manager, Novartis Oncology China, who shares insights on the pharmaceutical landscape of the country and the potential of partnerships with multinational corporations, followed by a conversation with Dr Farid Khan, CEO and Founder, PharmaKure, about the vital ongoing need for drug development and the scientific details behind biopharmaceuticals. 

If you’re interested in learning more about the topic areas discussed in this episode, check out the following content: 

Pharma in… China https://www.emg-gold.com/post/pharma-in-china 

A big boom in biotech https://www.emg-gold.com/post/a-big-boom-in-biotech 

A heyday for mRNA https://www.emg-gold.com/post/a-heyday-for-mrna  

The vast galaxy of neurology https://www.emg-gold.com/post/the-vast-galaxy-of-neurology 

Medical devices are an integral part to many procedures and treatments, and last month we started to investigate the vast and innovative world of these types of technologies in a two-part series on The Latest Dose. In part one, our esteemed guests, Dr. Khaudeja Bano, the executive medical director of combination product safety, global patient safety & pediatrics at Amgen; Nada Hanafi, the chief strategy officer at Experien Group; and Shruti Iyer, senior software reliability engineer at Medtronic, took us through the guidance and regulations surrounding medical devices, and highlighted one of the biggest trends in the space, artificial intelligence.

In part two, our guests are back to talk about another significant trend: virtual, augmented, and extended reality in medical devices. These devices are becoming essential in clinical research and healthcare, and are increasingly more innovative with each passing year. They’ll also discuss how to safely and effectively bring these new solutions to patients in a changing clinical world.

From bandaging a sprained ankle and diagnosing HIV/AIDS, to implanting an artificial hip and monitoring your heart, medical devices are an integral part to many medical procedures and treatments.

There is a lot to unpack when it comes to medical devices, so we’ve invited industry leaders Dr. Khaudeja Bano, the executive medical director of combination product safety, R&D strategy & operations, and global patient safety & pediatrics at Amgen; Nada Hanafi, the chief strategy officer at Experien Group; and Shruti Iyer, senior software reliability engineer at Medtronic, to share their thoughts in a two-part series of The latest Dose that will focus both on regulations and trends in medical devices.

In part one of episode 18, we discuss the guidance and regulations surrounding medical devices, and highlight one of the hottest trends in this space, artificial intelligence.

Aboard the HMS Salisbury of Britain’s Royal Navy on May 20th, 1747, surgeon James Lind performed what is often considered to be the first randomized clinical trial. Now, every May 20th, International Clinical Trials Day gives us a well-deserved occasion to honor and thank both the professionals and patients who make clinical research possible. It also gives us an opportunity to raise awareness of clinical research and show why it’s critical to the improvement of our health and wellness.

To help us celebrate Clinical Trials Day, we spoke with the Director of Patient Recruitment at Accellacare, ICON’s global clinical research network, Nazneen Qureshi. In this conversation, we discuss the role that volunteers and patients play in clinical research, how to recruit eligible people, and how to spread awareness and gratitude for clinical trial participants.

As a methodology that’s generally been underutilized in the past, the pandemic has brought telemedicine to the forefront as a way for doctors to care for their patients, without them having to come into an office or site. But how exactly is it being used in medicine and clinical research today, and will it still be widely used after the pandemic ends? In this discussion, Kathy speaks with Dr. Thomas Fiel and Everest Group's Nitish Mittal about how telemedicine is being used today, its benefits and challenges, how it impacts diversity in clinical trials, and if they think it will still be widely used post-pandemic.

Recently, Covance announced that they are transforming to a fully decentralized CRO – an exciting step in the life sciences industry. In this episode, Kathy speaks with Covance’s Director of Decentralized Trials, Jane Myles, and Vice President and Head of Decentralized Trials, Bola Oyegunwa, about how they’re driving the implementation of decentralized trials globally, and what they think the core tenants are that the industry should abide by when executing decentralized trials.

Clinical Trial Transformation Initiative (CTTI) announced on January 25, 2021, a new vision for clinical trial ecosystem and beyond, called Transforming Trials 2030. The pandemic has changed the way we perform clinical research, and many constituents have implemented new and efficient solutions, systems, and processes to conduct trials. CTTI members believe this passion and experience will help shape a future of smarter, faster research. In this episode, Kathy speaks with Dr. Pamela (Pam) Tenaerts, executive director at CTTI, about CTTI’s vision for the future of clinical research, Transforming Trials 2030.